<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00564200</url>
  </required_header>
  <id_info>
    <org_study_id>2005-004858-27</org_study_id>
    <nct_id>NCT00564200</nct_id>
  </id_info>
  <brief_title>MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning</brief_title>
  <acronym>MINIALO-VELCAD</acronym>
  <official_title>MINIALO-VELCADE2005: A Phase II National, Open-label, Multicenter, no Controlled Study of Treated With Bortezomib (Velcade) Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to analyze the efficacy of allogeneic bone marrow&#xD;
      transplantation in a reduced-intensity manner combined with bortezomib in the treatment of&#xD;
      multiple myeloma with bad prognosis, in order to evaluate the response and relapse rates&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple Myeloma is a plasma cell disorder characterized by an uncontrolled proliferation of&#xD;
      bone marrow plasma cells leading to skeletal destruction with bone pain, anemia, renal&#xD;
      failure, hypercalcemia, recurrent bacterial infections and extramedullary plasmacytomas. It&#xD;
      accounts for 1% of all malignancies and slightly more than 10% of hematologic malignancies,&#xD;
      with an annual incidence of about four per 100.000. Although this disease is incurable with a&#xD;
      median survival of about 3 years, remarkable treatment advances have been recently made,&#xD;
      including high-dose therapy followed by stem cell rescue and, particularly, the introduction&#xD;
      of novel promising agents with new mechanisms of action.&#xD;
&#xD;
      The treatment with alquilant agents, melphalan or cyclophosphamide combined with prednisone&#xD;
      has a median of no more than 3 years survival rate in approximately 50%. The chemotherapy&#xD;
      combination and high-dose dexamethasone increases response rate with minimal effects in&#xD;
      survival benefit. The limited efficacy of conventional treatment produced the introduction of&#xD;
      the high-dose therapy followed by a stem cells transplant in order to increase antitumoral&#xD;
      effect and prolong disease-free overall survival.&#xD;
&#xD;
      This way, autologous stem cells transplant has turned into optimal treatment for patients&#xD;
      younger than 65 years with myeloma. Nevertheless there is increasing evidence that it&#xD;
      benefits only patients who showed complete disease remission after transplantation.&#xD;
&#xD;
      The transcendental factor that determines the CR post-transplantation achievement is the&#xD;
      initial chemotherapy- sensitivity disease, measuring the rapidity and the grade of response&#xD;
      (rapidity of maximum response assessment) and the pre-transplantation M protein level (i.e.,&#xD;
      the grade of response to the initial treatment).&#xD;
&#xD;
      On the other hand, the treatments with alquilant agents can impede the obtention of adequate&#xD;
      numbers of stem cells that make impossible the autotransplantation practice. For this reason&#xD;
      nowadays the treatments based on dexamethasone are used as initial chemotherapy.&#xD;
&#xD;
      However, these regimens and particularly AVD have less activity than alquilant agents&#xD;
      treatment. Bortezomib has shown a fast antimyeloma activity (response after 1 or 2 cycles) in&#xD;
      refractory patients, where myelosuppression and cellular injury are not observed.&#xD;
&#xD;
      Alternating bortezomib and dexamethasone as pre-transplant induction regimen would show the&#xD;
      following advantages:&#xD;
&#xD;
        1. a rapid and high effect raised by means of the use of two drugs with proven activity&#xD;
           when they are administered separately,&#xD;
&#xD;
        2. absence of stem cells injury,&#xD;
&#xD;
        3. different toxicity types avoiding the habitual side effects because of the dexamethasone&#xD;
           abuse, when this one is administered in every cycle as it happens in AVD type regimens.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analyze the efficacy of allogeneic bone marrow transplantation in a reduced-intensity manner combined with bortezomib</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>PREACONDICIONAMIENTO:&#xD;
2 cycles of 21 days : Velcade days: 1, 4, 8 and 11&#xD;
1 cycle of 13 days : Velcade days 1, 4, 8 and 11&#xD;
ACONDICIONAMIENTO:&#xD;
- Day -2: Velcade&#xD;
POSTRANSPLANTATION:&#xD;
2 cycles of 21 days : Velcade days 1, 8 and 15&#xD;
5 cycles of 56 days : Velcade days 1, 8 and 15</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>PREACONDICIONAMIENTO:&#xD;
- 2 cycles of 21 days : Dexamethasone: days 1-4 and 8-11</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>ACONDICIONAMIENTO:&#xD;
- Days -9 al -5: Fludarabine</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>ACONDICIONAMIENTO:&#xD;
- Days -4 and -3: Melphalan.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is, in the investigator's opinion, willing and able to comply with the&#xD;
             protocol requirements.&#xD;
&#xD;
          -  Patient has given voluntary written informed consent before performance of any&#xD;
             study-related procedure not part of normal medical care, with the understanding that&#xD;
             consent may be withdrawn by the patient at any time without prejudice to their future&#xD;
             medical care.&#xD;
&#xD;
          -  Age over 18 and under 67 years old.&#xD;
&#xD;
          -  Patient diagnosed with symptomatic Multiple Myeloma based on standard criteria with&#xD;
             bad prognosis. This factor is associated with at least one of the clinical alterations&#xD;
             defined as follows:&#xD;
&#xD;
        Patient who displayed a Monosomy of chromosome 13 or other adverse cytogenetic abnormality.&#xD;
&#xD;
        Patient in first relapse. Patient with relapsed multiple myeloma after autologous&#xD;
        transplantation.&#xD;
&#xD;
          -  Patient has a ECOG performance status &lt;= 2.&#xD;
&#xD;
          -  Patient has a life-expectancy &gt;3 months.&#xD;
&#xD;
          -  Patients who are candidates for autologous transplantation.&#xD;
&#xD;
          -  Patients must have HLA-identical sibling donors.&#xD;
&#xD;
          -  Patient has the following laboratory values before Baseline visit:&#xD;
&#xD;
        Platelet count ≥ 30000/mm3 (transfusion allowed), hemoglobin ≥ 8 g/dl (transfusion allowed)&#xD;
        and absolute neutrophil count (ANC) ≥ 0.750/mm3. Lower values are accepted if they are&#xD;
        caused by bone marrow infiltration.&#xD;
&#xD;
        Aspartate transaminase (AST): ≤ 2.5 x the upper limit of normal. Alanine transaminase&#xD;
        (ALT): ): ≤ 2.5 x the upper limit of normal. Total bilirubin: ≤1.5 x the upper limit of&#xD;
        normal. Serum creatinine value ≤ 2mg/dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient present serious pathologies that make impossible chemotherapy treatments:&#xD;
&#xD;
               1. Congestive heart failure, angina or heart attack during last 12 months.&#xD;
&#xD;
               2. Uncontrolled arterial hypertension.&#xD;
&#xD;
               3. Uncontrolled supraventricular arrhythmias during last 3 last months.&#xD;
&#xD;
               4. Ventricular arrhythmia.&#xD;
&#xD;
               5. Hepatic disease (Cirrhosis).&#xD;
&#xD;
          -  Patient has Grade 2 peripheral neuropathy within 14 days before enrollment.&#xD;
&#xD;
          -  Patient with serious psychiatric disorders that make impossible comply satisfactorily&#xD;
             with the protocol requirements.&#xD;
&#xD;
          -  Personal medical history of neoplasia of other type, except: carcinoma in situ, other&#xD;
             curatively treated malignancy in complete remission for more than 10 years.&#xD;
&#xD;
          -  Patient has hypersensitivity to bortezomib, boron or mannitol.&#xD;
&#xD;
          -  Fertile patient is not going to use a medical effective contraceptive method during&#xD;
             the trial.&#xD;
&#xD;
          -  Patient has received other investigational drugs within 30 days before enrollment&#xD;
&#xD;
          -  Patient is known to be seropositive for the human immunodeficiency virus (HIV),&#xD;
             Hepatitis B surface antigen-positive or active hepatitis C infection.&#xD;
&#xD;
          -  Patient had a myocardial infarction within 6 months of enrollment or has New York&#xD;
             Heart Association (NYHA) Class III or IV, heart failure, uncontrolled angina, severe&#xD;
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute&#xD;
             ischemia or active conduction system abnormalities.&#xD;
&#xD;
          -  Patient is enrolled in another clinical research study and/or is receiving an&#xD;
             investigational agent for any reason.&#xD;
&#xD;
          -  Patient participated in clinical study VISTA.&#xD;
&#xD;
          -  Pregnant or breast-feeding women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bladé Joan, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Clinic I Provincial</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. de la Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Catalán de Oncología</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. de Jerez</name>
      <address>
        <city>Jerez de la Frontera</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Univ. Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Univ. La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Univ. Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Univ. Son Dureta</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Univ. de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.aehh.org</url>
    <description>Spanish association of Haematology</description>
  </link>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>November 26, 2007</study_first_submitted>
  <study_first_submitted_qc>November 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2007</study_first_posted>
  <last_update_submitted>October 27, 2014</last_update_submitted>
  <last_update_submitted_qc>October 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma, transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

